A NEW experimental cancer jab could one day be used to fight any type of tumour, US scientists claim.
Experts from the University of Florida say they’ve developed a powerful that trains the to target and destroy .
It’s dubbed the “one-two punch”; after the powerful boxing move where a jab sets up a cross to knock the opponent down.
This is because this jab also works in two steps: first by waking up the immune system, then helping it attack cells more effectively.
It does this by boosting the effects of , a type of cancer treatment that helps the immune system recognise and attack cancer cells.
The groundbreaking discovery brings us closer to a universal cancer jab that could work across many tumour types, it is hope
Research in mice showed that combining the jab with a common immunotherapy drug called an immune checkpoint inhibitor helped fight even resistant tumours.
Dr Elias Sayour, the study’s senior author, said: “This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumour or virus, so long as it is an mRNA vaccine, could lead to tumour-specific effects.”;
He added: “This finding is a proof of concept that these vaccines potentially could be commercialised as universal cancer vaccines to sensitise the immune system against a patient’s individual tumour.”;
Unlike previous cancer vaccines that try to hone in on a particular protein in the cell, the new jab works by simply firing up the immune system, tricking it into responding as if it were under viral attack.
By boosting levels of a protein called PD-L1 inside tumours, it makes them more receptive to immunotherapy and helps immune cells recognise them as dangerous.
Lead scientist Dr Duane Mitchell, co-author of the study, said: “What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction.
“And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine.”;
For the past eight years, Dr Sayour’s lab has been developing cutting-edge vaccines using the same mRNA technology found in Covid jabs.
Last year, they in four patients with – an aggressive and usually deadly brain tumour.
They saw a fast and fierce immune response that helped fight off the cancer.
The latest study, published today in Nature Biomedical Engineering, tested a more generalised version of the jab, not tailored to individual tumours, and still saw dramatic results.
In mice with , a type of deadly , combining the jab with an immunotherapy drug called a PD-1 inhibitor led to tumour shrinkage
While in some skin, bone, and brain cancer models, the jab alone eliminated tumours completely.
Dr Sayour explained: “Even an immune response that is seemingly unrelated to the cancer may be able to activate T cells that weren’t working before, allowing them to multiply and kill the tumour if the response is strong enough.”;
Dr Mitchell said: “It could potentially be a universal way of waking up a patient’s own immune response to cancer.
“And that would be profound if generalisable to human studies.”;
The team are now working to improve the formula and begin human trials as soon as possible.
